FDA Inspection
North American Custom Laboratories, LLC dba FarmaKeio Superior Custom CompoundingNorth American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding – FDA Inspection, Sep 5, 2025
Record Details
This FDA Inspection record concerns North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding, with an inspection on September 5, 2025, issued by the Dallas District Office, covering human drugs.
- Inspection Date
- September 5, 2025
- Product Type
- Human Drugs
View Company Profile
ID · c27b65d6-4ba0-4c25-8c22-7de5cfd3de16
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1280796
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
5- 21 CFR 110.35(a)Buildings/good repair
- 21 CFR 110.35(d)Failure to clean - general
- 21 CFR 110.80(b)(2)Manufacturing conditions
- 21 CFR 110.93Storage/transportation of finished goods (contamination)
- FD&C Act 501(a)(2)(A)Production areas, difficult to clean/particle generating
Full citation text and observation details available on the Dashboard.
Other FDA inspections of North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
1| Date | Classification | Office | Project area |
|---|---|---|---|
| March 10, 2022 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.